Related Experiment Video

Updated: Mar 20, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K

Targeting mTOR in Pancreatic Ductal Adenocarcinoma

Sentia Iriana1, Shahzad Ahmed1, Jun Gong2

  • 1Department of Medicine, Cedars-Sinai Medical Center , Los Angeles, CA , USA.

Frontiers in Oncology
|May 21, 2016
PubMed

Insights

Targeting the mammalian target of rapamycin (mTOR) pathway shows promise for KRAS-dependent pancreatic cancer. Combined inhibition may overcome resistance and offer new treatment options for advanced pancreatic ductal adenocarcinoma (PDAC).

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Advanced pancreatic ductal adenocarcinoma (PDAC) has limited treatment options.
  • KRAS mutations are common drivers in PDAC, presenting therapeutic targets.
  • The mammalian target of rapamycin (mTOR) pathway is implicated in PDAC tumorigenesis.

Purpose of the Study:

  • To explore the potential of targeting the mTOR pathway in specific KRAS-dependent PDAC subtypes.
  • To investigate combination therapies for overcoming resistance to mTOR inhibition.
  • To identify future therapeutic strategies for advanced PDAC.

Main Methods:

  • Review of preclinical data on mTOR inhibition in KRAS-dependent PDAC.
  • Analysis of early phase II studies on monotherapy mTOR inhibition.
  • Evaluation of studies on combined mTOR pathway inhibition.

Main Results:

  • Preclinical studies show mTOR inhibition suppresses tumorigenesis in specific KRAS-dependent PDAC subtypes.
  • Early phase II studies of single-agent mTOR inhibition yielded disappointing results.
  • Combined inhibition targeting multiple mTOR pathway steps may overcome resistance and improve responses.

Conclusions:

  • Targeted mTOR inhibition in combination with other agents may offer a viable treatment strategy for specific PDAC subpopulations.
  • Coordinated inhibition of mTOR and KRAS-dependent pathways warrants further investigation for advanced PDAC.
  • Future research should focus on molecularly defined PDAC subpopulations for personalized therapy.
Keywords:
KRASclinical trialsmTORpancreatic ductal adenocarcinomapreclinical

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

12.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K